One Wealth Advisors LLC Acquires New Position in AstraZeneca PLC (NASDAQ:AZN)

One Wealth Advisors LLC bought a new position in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,534 shares of the company's stock, valued at approximately $260,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Confluence Investment Management LLC acquired a new position in shares of AstraZeneca during the 1st quarter valued at $27,000. Larson Financial Group LLC lifted its holdings in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after acquiring an additional 289 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of AstraZeneca during the 1st quarter valued at $29,000. Banque Transatlantique SA acquired a new position in shares of AstraZeneca during the 4th quarter valued at $26,000. Finally, Highline Wealth Partners LLC lifted its holdings in shares of AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock valued at $31,000 after acquiring an additional 340 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AZN. BNP Paribas began coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $89.00.

AstraZeneca Stock Down 1.4%

AZN stock traded down $1.02 during trading on Friday, reaching $72.66. The stock had a trading volume of 6,200,753 shares, compared to its average volume of 3,846,153. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $225.34 billion, a P/E ratio of 29.18, a PEG ratio of 1.35 and a beta of 0.37. The firm has a fifty day moving average price of $71.15 and a 200 day moving average price of $71.11.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.06 EPS. On average, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.